Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Death at final · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in death at final compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Death · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether mechanical thrombectomy changes death compared with pulse spray technique (very low certainty).
1 finding from 1 review
Death · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review